IMCT-04TOCA 5: PHASE 2/3 RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 WITH TOCA FC VERSUS STANDARD OF CARE IN PATIENTS UNDERGOING PLANNED RESECTION FOR RECURRENT HIGH GRADE GLIOMA (NCT02414165)
Bibliographic record
Abstract
Recurrent glioblastoma and anaplastic astrocytoma have a dismal prognosis and a high unmet need for effective therapies. Toca 511 is a retroviral replicating vector derived from a cloned Moloney murine leukemia virus with the original ecotropic envelope gene replaced with an amphotropic envelope gene to enable the virus to infect human cells. A modified yeast cytosine deaminase (CD) gene has been inserted into this vector. The expressed CD enzyme catalyzes conversion of antifungal drug 5-flucytosine (administered as investigational extended-release formulation Toca FC) to antineoplastic drug 5-fluorouracil. Toca 5 is a multicenter, randomized, open-label Phase 2/3 trial of Toca 511 and Toca FC versus standard of care (Investigator's choice of single agent lomustine, temozolomide, or bevacizumab) administered to patients undergoing resection for first or second recurrence of glioblastoma or anaplastic astrocytoma. The trial will enroll approximately 370 patients (Phase 2-170 and Phase 3-200). Primary endpoint is overall survival (OS). Key secondary endpoints are safety, objective response rate, clinical benefit rate, progression-free survival, and landmark OS. Key inclusion criteria are age 18-75 years, histologically proven glioblastoma or anaplastic astrocytoma, measurable disease preoperatively of at least 1 cm, candidate for ≥ 80% resection of enhancing tumor based on pre-operative evaluation, KPS ≥ 70. Selected exclusion criteria are enhancing tumor > 5 cm, more than two prior recurrences and prior bevacizumab other than for newly diagnosed glioma. Assays will be performed to evaluate evidence for immunologic mechanisms of disease control, including tumor reactive PBMC measurement by stimulation via ex vivo glioma antigen presentation, flow cytometry based phenotyping of PBMCs with an effector, memory, Treg, and myeloid derived suppressor cell panel. Molecular profiling of resected tumor samples will be correlated with primary and secondary endpoints to identify potential biomarkers for treatment-related response. Toca 5 is expected to begin enrollment in 3Q 2015.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.003 | 0.004 |
| Insufficient payload (model declined to judge) | 0.010 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".